Back to Search
Start Over
University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL.
- Source :
-
British journal of haematology [Br J Haematol] 2018 Apr; Vol. 181 (2), pp. 264-267. Date of Electronic Publication: 2017 Apr 17. - Publication Year :
- 2018
- Subjects :
- Adult
Aged
Aged, 80 and over
Benzimidazoles adverse effects
Chicago
Disease-Free Survival
Female
Humans
Lymphoma, Large B-Cell, Diffuse pathology
Male
Middle Aged
Survival Rate
Benzimidazoles administration & dosage
Lymphoma, Large B-Cell, Diffuse drug therapy
Lymphoma, Large B-Cell, Diffuse mortality
Subjects
Details
- Language :
- English
- ISSN :
- 1365-2141
- Volume :
- 181
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- British journal of haematology
- Publication Type :
- Report
- Accession number :
- 28419407
- Full Text :
- https://doi.org/10.1111/bjh.14544